A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with ...

Eli Lilly announced that its breakthrough drug, Mounjaro (tirzepatide), has received marketing authorization from India’s ...

Boots Online Doctor has revealed the 'very common' side-effects of Mounjaro you need to know about after thousands of people ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.

India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, ...

GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only ...

The next generation of diabetes and weight loss drugs could come in pill form, deliver even greater weight loss results, and ...

In adults with obesity and prediabetes, weight loss achieved with tirzepatide was sustained at more than 3 years, according ...

GPs fear a wave of complaints from patients hoping to access the weight-loss drug tirzepatide in primary care - amid warnings ...

Editor Sofia Lind questions the lack of planning, support and infrastructure for GPs among the rollout of tirzepatide in ...

Catch up quickly with our weekly round-up of key news stories for general practice.